BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35779346)

  • 41. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
    Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiparametric functional MRI and
    Martens RM; Koopman T; Lavini C; Ali M; Peeters CFW; Noij DP; Zwezerijnen G; Marcus JT; Vergeer MR; Leemans CR; de Bree R; de Graaf P; Boellaard R; Castelijns JA
    Eur Radiol; 2021 Feb; 31(2):616-628. PubMed ID: 32851444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of positron emission tomography with computed tomography for image-guided radiotherapy.
    Isnardi V; Thureau S; Vera P
    Cancer Radiother; 2020 Aug; 24(5):362-367. PubMed ID: 32284178
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Positron emission tomography in the evaluation of stage III and IV head and neck cancer.
    Teknos TN; Rosenthal EL; Lee D; Taylor R; Marn CS
    Head Neck; 2001 Dec; 23(12):1056-60. PubMed ID: 11774391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
    Staal FHE; Janssen J; Brouwer CL; Langendijk JA; Ng Wei Siang K; Schuit E; de Jong IJ; Verzijlbergen JF; Smeenk RJ; Aluwini S
    BMC Cancer; 2022 Apr; 22(1):416. PubMed ID: 35428210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional Imaging to Predict Treatment Response in Head and Neck Cancer: How Close are We to Biologically Adaptive Radiotherapy?
    Paterson C; Hargreaves S; Rumley CN
    Clin Oncol (R Coll Radiol); 2020 Dec; 32(12):861-873. PubMed ID: 33127234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
    Vale CL; Fisher D; Kneebone A; Parker C; Pearse M; Richaud P; Sargos P; Sydes MR; Brawley C; Brihoum M; Brown C; Chabaud S; Cook A; Forcat S; Fraser-Browne C; Latorzeff I; Parmar MKB; Tierney JF;
    Lancet; 2020 Oct; 396(10260):1422-1431. PubMed ID: 33002431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fast neutron radiation therapy. Results of phase III randomized trials in head and neck, lung, and prostate cancers.
    Koh WJ; Griffin TW; Laramore GE; Stelzer KJ; Russell KJ
    Acta Oncol; 1994; 33(3):293-8. PubMed ID: 8018358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer.
    Moule RN; Kayani I; Prior T; Lemon C; Goodchild K; Sanghera B; Wong WL; Saunders MI
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):364-71. PubMed ID: 21109410
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
    Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
    Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
    Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
    Menda Y; Graham MM
    Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin.
    Fayter D; Corbett M; Heirs M; Fox D; Eastwood A
    Health Technol Assess; 2010 Jul; 14(37):1-288. PubMed ID: 20663420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.